Replies to post #182982 on Biotech Values

[frontiers]

what’s unique about ACH-3422 is that some sell-side analysts have hyped the monotherapy data to be presented at AASLD as some kind of pivotal moment for the HCV arena.

The FBR analyst mentioned the preclinical 3422 data at AASLD but that's a rehash of old stuff IMO and a non-event. They are not presenting the 3422 monotherapy data from the 3422 trial at AASLD ... I am not aware of any analysts having hyped that ... the release of 3422 trial data will be a pivotal event ... that trial is in the good hands of Prof Gane and it will be run well!